Low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) for haemodialysis anticoagulation

Xie, Xi; Yang, Kun; Zuo, Chuantao; Fan, Junming

doi:10.1002/14651858.cd008196

Cited by 1 publication

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The anticoagulation activity of UFH is relatively complex, and it involves a variety of binding sites of clotting factors, thus the UFH may affect the counts and function of platelets, resulting in a relatively high incidence of bleeding and thrombocytopenia. However, LMWH mainly combines with antithrombin III and has little effect on other clotting factors; thus, bleeding and thrombocytopenia are relatively rare . To estimate the toxicity of LH–DOX and evaluate the effect of UFH and LMWH, a hematology analysis was performed.…”

Section: Resultsmentioning

confidence: 99%

“…However, LMWH mainly combines with antithrombin III and has little effect on other clotting factors; thus, bleeding and thrombocytopenia are relatively rare. 42 To estimate the toxicity of LH−DOX and evaluate the effect of UFH and LMWH, a hematology analysis was performed. The WBC (white blood cell) count of DOX-treated mice dropped by nearly 30% compared to the saline group.…”

Section: Molecular Pharmaceuticsmentioning

confidence: 99%

See 1 more Smart Citation

Polymer–Drug Nanoparticles Combine Doxorubicin Carrier and Heparin Bioactivity Functionalities for Primary and Metastatic Cancer Treatment

et al. 2017

View full text Add to dashboard Cite

Here, a biocompatible amphiphilic copolymer of low molecular weight heparin (LMWH) and doxorubicin (DOX) connected by an acid-sensitive hydrazone bond for enhanced tumor treatment efficacy and safety has been designed and tested. The conjugate combines DOX delivery with LMWH antimetastatic capabilities. After the nanoparticles reach the tumor site, the acidic tumor microenvironment triggers the breakage of the hydrazone bond releasing DOX from the nanoparticles, which results in an increase in the cellular uptake and enhanced in vivo antitumor efficacy. A 3.4-fold and 1.5-fold increase in tumor growth inhibition were observed compared to the saline-treated control group and free DOX treated group, respectively. The LMWH-based nanoparticles effectively inhibited interactions between tumor cells and platelets mediated by P-selectin reducing metastasis of cells in both in vitro and in vivo models. The improved safety and therapeutic effect of LMWW-DOX nanoparticles offers new potential for tumor therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Molecular Pharmaceuticsmentioning

confidence: 99%